KURA — Kura Oncology, Inc.

Kura Oncology, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Revenue: $2.1 million from Comzifty sales in the final weeks of 2025, a significant increase from $0 in 2024.
• Collaboration Revenue: $15.2 million from Kyowa Kirin, down from $53.9 million in 2024.
• R&D Expenses: Increased to $64.4 million from $52.3 million in 2024, driven by ziftomenib combination trials.
• SG&A Expenses: Rose to $39.1 million from $24.1 million in 2024, reflecting the commercial launch of Comzifty.
• Net Loss: $81 million for 2025, compared to $19.2 million in 2024.
• Cash Position: $667.2 million as of December 31, 2025, down from $727.4 million in 2024, but includes $195 million from Comzifty sales and milestone payments.

2. Strategic Updates and Business Highlights

• FDA Approval: Comzifty received FDA approval and has initiated a successful commercial launch.
• Market Positioning: Kura aims to establish Comzifty as a leader in the menin inhibitor class, particularly for relapsed/refractory NPM1-mutant AML.
• Pipeline Development: Enrollment in the pivotal COMET-017 frontline trials is underway, with plans to expand into combination therapies with FLT3 inhibitors.
• Market Opportunity: The total U.S. market opportunity for AML is estimated at approximately $7 billion, with initial expectations for relapsed/refractory NPM1-mutant AML at $350 million to $400 million annually.
• Combination Strategies: Advancing combinations of ziftomenib with other therapies, including imatinib for GIST and darlafarnib for solid tumors.

3. Forward Guidance and Outlook

• Revenue Guidance: Expected collaboration revenue of $45 million to $55 million in 2026, increasing to $90 million to $110 million in 2027 and 2028.
• Clinical Updates: Multiple updates anticipated in 2026, including data from frontline and relapsed/refractory settings.
• Focus Areas: Priorities include accelerating Comzifty uptake, expanding development in AML, and delivering clinical updates across the pipeline.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The substantial increase in net loss raises concerns about financial sustainability, particularly with rising R&D and SG&A expenses.
• Market Penetration Risks: The company faces challenges in gaining market share, particularly in the competitive landscape of AML treatments, where prescriber inertia and combination therapy uptake may impact growth.
• Dependence on Combination Data: Future success may hinge on the ability to demonstrate effective combination therapies, which are not yet fully validated.

5. Notable Q&A Insights

• Step Edit Policy: Some payers are requiring Comzifty to be used before other menin inhibitors, indicating strong early market positioning.
• Patient Demand: Early feedback indicates strong demand and positive reception from physicians and pharmacists regarding Comzifty’s profile.
• Combination Therapy Potential: Physicians are interested in using Comzifty in combination settings, which could drive future growth but remains to be validated through clinical data.
• Duration of Therapy: While it is early to assess, initial expectations suggest an average treatment duration of six months, with potential for longer durations when combined with other therapies.

Overall, Kura Oncology is entering 2026 with a strong commercial launch of Comzifty and a robust pipeline, but faces challenges related to financial losses and competitive pressures in the AML market.